Role of Serotonin_2A and Serotonin_2B/2C Receptor Subtypes in the Control of Accumbal and Striatal Dopamine Release Elicited In Vivo by Dorsal Raphe Nucleus Electrical Stimulation

10.1016/0028-3908(95)00138-7

Ashby C.H.J, 1996, Differential effect of the 5‐HT2B/2C receptor antagonist SB 200646 and the selective 5‐HT2A antagonist MDL 100907 on midbrain dopamine (DA) neurons in rats : an electrophysiological study., Soc. Neurosci. Abstr., 22, 1323

10.1002/ddr.430150107

10.1002/cne.901790311

10.1016/S0165-6147(00)88991-9

10.1016/0028-3908(94)00145-I

10.1002/(SICI)1098-2396(199607)23:3<125::AID-SYN1>3.3.CO;2-P

De Deurwaerdère P., 1998, Opposite change of in vivo dopamine release in the rat nucleus accumbens and striatum that follows electrical stimulation of dorsal raphe nucleus : role of 5‐HT3 receptors., J. Neurosci., 18, 6528, 10.1523/JNEUROSCI.18-16-06528.1998

10.1016/0006-8993(87)90683-4

Deutch A.Y., 1991, Mechanisms of action of atypical antipsychotic drugs. Implication for novel therapeutic strategies for schizophrenia., Schizophr. Res., 4, 21, 10.1016/0920-9964(91)90030-U

Dewey S.T., 1995, Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis., J. Neurosci., 15, 821, 10.1523/JNEUROSCI.15-01-00821.1995

Di Giovanni G., 1997, Selective blockade of serotonin2c receptors enhances mesostriatal and mesolimbic dopaminergic function. (Abstr.), Trends Neurosci., 20, 9

10.1016/S0028-3908(98)00014-8

Duxon M.S., 1995, Expression of 5‐HT2B receptor protein in the rat., Br. J. Pharmacol., 115, 105P

10.1002/(SICI)1096-9861(19970728)384:2<233::AID-CNE5>3.0.CO;2-2

10.1016/0306-4522(77)90120-8

10.1111/j.1476-5381.1995.tb13236.x

10.1016/0024-3205(94)00876-0

10.1016/0014-2999(94)90669-6

10.1111/j.1471-4159.1992.tb10975.x

10.1111/j.2042-7158.1980.tb12889.x

10.1176/ajp.153.4.466

10.1016/S0893-133X(98)00072-4

Kelland M.D., 1990, Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons., J. Pharmacol. Exp. Ther., 253, 803

10.1016/0361-9230(93)90121-Q

10.1111/j.1476-5381.1996.tb15208.x

10.1016/S0006-8993(98)00338-2

Lejeune F., 1997, Serotonin (5‐HT2C) receptors inhibit the activity of mesocortical and mesolimbic dopaminergic pathways : a combined dialysis and electrophysiological analysis., Soc. Neurosci. Abstr., 23, 975

Leysen J.E., 1985, Receptor‐binding properties in vitro and in vivo of ritanserin, a very potent and long acting serotonin S2 antagonist., Mol. Pharmacol., 27, 600

10.1007/BF02245006

10.1007/BF01277672

Meltzer H.Y., 1991, Effects of antipsychotic drugs on serotonin receptors., Pharmacol. Rev., 43, 587

10.1016/0306-4522(90)90330-7

10.1016/0306-4522(93)90241-7

10.1016/S0306-4522(96)00452-6

10.1016/0024-3205(90)90484-9

10.1113/jphysiol.1989.sp017786

OffordS.J.(1998)M100907 a highly selective 5‐HT2Aantagonist for treatment of schizophrenia : early indication of safety and clinical activity in schizophrenic patients (Abstr.) inXXIst Collegium Internationale Neuro‐Psychopharmacologicum Congress Glasgow PT10052. Cambridge University Press.

10.1007/BF02246453

PaxinosG.&WatsonC.(1986)The Rat Brain in Stereotaxic Coordinates 2nd edit. Academic Press Orlando.

10.1016/0006-8993(85)90857-1

10.1016/0024-3205(92)90423-M

10.1016/0006-8993(94)90495-2

10.1016/0169-328X(94)90223-2

10.1111/j.1476-5381.1995.tb16684.x

Prisco S., 1994, Serotonin‐dopamine interaction in the rat ventral tegmental area : an electrophysiological study in vivo., J. Pharmacol. Exp. Ther., 271, 83

10.1007/s002130050454

Rinaldi‐Carmona M., 1992, Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5‐hydroxytryptamine2 receptor antagonist., J. Pharmacol. Exp. Ther., 262, 759

Schmidt C.J., 1996, Regional effects of MK‐801 on dopamine release : effects of competitive NMDA or 5‐HT2A antagonists receptor blockade., J. Pharmacol. Exp. Ther., 277, 1541

10.1016/0014-2999(92)90819-P

10.1016/0024-3205(95)00210-W

Schreiber R., 1995, 1‐(2,5‐Dimethoxy‐4‐iodophenyl)‐2‐aminopropane)‐induced head‐twitches in the rat are mediated by 5‐hydroxytryptamine (5‐HT)2A receptors : modulation by novel 5‐HT2A/C antagonists, D1 antagonists and 5‐HT1A agonists., J. Pharmacol. Exp. Ther., 273, 101

10.1111/j.1471-4159.1989.tb07319.x

Shi W., 1995, Ritanserin, a 5‐HT2A/2C antagonist, reverses direct dopamine agonist‐induced inhibition of midbrain dopamine neurons., J. Pharmacol. Exp. Ther., 274, 735

10.1016/0006-8993(89)90486-1

Sorensen S.M., 1993, Characterization of the 5‐HT2 receptor antagonist MDL 100,907 as a putative atypical antipsychotic : behavioral, electrophysiological and neurochemical studies., J. Pharmacol. Exp. Ther., 266, 684

10.1111/j.1471-4159.1985.tb04092.x

10.1002/cne.903340408

10.1016/0006-8993(94)91330-7

10.1016/S0006-8993(97)01267-5

10.1016/0014-2999(88)90110-0